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Abstract
Background: Lipocalin-2 is a novel adipokine with connection to insulin resistance. In this study, we aimed to
investigate the association of serum lipocalin-2 with glucose metabolism and other metabolic phenotype in a
large-scale Chinese population.
Methods: We evaluated serum lipocalin-2 in a cross-sectional sample of 2519 Chinese aged from 50 to 82 year in
a Shanghai downtown district by ELISA. Glucose, insulin, lipid profile, inflammatory markers, and adipokines were
also measured.
Results: Serum lipocalin-2 was significantly higher in subjects with isolated impaired fasting glucose, isolated
impaired glucose tolerance, combined impaired fasting glucose/impaired glucose tolerance and newly-diagnosed
type 2 diabetes than in those with normal glucose regulation. Lipocalin-2 elevation was clearly associated with a
higher risk for impaired glucose regulation (OR 1.30 for each 10 ng/ml increase in serum lipocalin-2, 95% CI 1.23-
1.62, p = 0.009) after adjustment of age, gender, smoking, alcohol drinking, family history of diabetes, serum CRP,
serum adiponectin, serum CXCL5, HOMA-IR, BMI, and waist/hip ratio. The OR for participants with impaired glucose
regulation and type 2 diabetes was 1.31 (95% CI 1.21-1.69, p < 0.001).
Conclusions: Our findings suggest that elevated serum lipocalin-2 is closely and independently associated with
impaired glucose regulation and type 2 diabetes.
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Background
Obesity is a major risk factor for insulin resistance. It is
well known that adipocytes could secrete a variety of
biologically adipokines, which are thought to contribute
to the development of insulin resistance and cardiovas-
cular disease [1-3]. Lipocalin-2, a recently identified adi-
pokine with high levels of expression and secretion in
the white adipose tissue, seems to affect glucose meta-
bolism and insulin sensitivity.
Lipocalin-2, also known as neutrophil gelatinase-asso-
ciated lipocalin, neu-related lipocalin, siderocalin, utero-
calin, and 24p3, belongs to the lipocalin super family. It
shows high affinity to several small hydrophobic ligands
such as retinoids, fatty acids, pheromones, steroids and
iron [4-6]. Lipocalin-2 was found expressed in kidney,
brain, lung, liver, neutroph i l s ,a d i p o c y t e sa sw e l la s
macrophages and was involved in varieties of biological
functions such as apoptosis, tumorigenesis and innate
immunity [7-9].
Recent studies in animal models showed that lipocalin-2
also plays an important role in systemic insulin sensitivity
and glucose homeostasis [10,11]. Lipocalin-2 suppression
could attenuate aging and obesity-induced insulin resis-
tance [12]. In human studies, it was reported that lipoca-
lin-2 levels were elevated in both circulation and adipose
tissue of obese people. Moreover, circulating lipocalin-2
concentration was positively correlated with insulin resis-
tance index and inflammatory markers [11,13]. Further-
more, elevated serum lipocalin-2 levels were also observed
among diabetic patients, and this increase could be
reversed by the insulin-sensitizing drug rosiglitazone [11].
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any medium, provided the original work is properly cited.However, evidence from large-scale populations about the
relationship between lipocalin-2 and glucose metabolism,
insulin resistance and chronic low-grade systemic inflam-
mation is scarce.
To better evaluate the role of lipocalin-2 in glucose
metabolism, insulin resistance and chronic Low-grade sys-
temic inflammation, we explored the association of serum
lipocalin-2 levels with chronic inflammatory marker, insu-
lin resistance and glucose metabolism states in a large-
scale Chinese population. We examined lipocalin-2 distri-
bution in 2519 middle-aged and older Chinese subjects in
a cross-sectional study and explored the association of
serum lipocalin-2 levels with glucose metabolism as well
as other metabolic parameters.
Methods
Study population
The design and recruitment of the population-based
cross-sectional study has been described in detail else-
where [14]. In 2007 China launched a national incidence
trends of metabolic syndrome study. The data presented
in this article are partially based on subsamples from
Shanghai in eastern China (total 2598 subjects). All stu-
died individuals came from the Simenerlu community of
the Jingan District and the Jiangninglu community of the
Putuo District in Shanghai, China. A multistage stratified
cluster sampling method was used to select subjects from
these two communities. Only one participant (> 50 year)
was randomly selected from each household. In these
2598 subjects, 79 participants have previously diagnosed
type 2 diabetes, all the others received the oral glucose tol-
erance test and 392 are newly diagnosed type 2 diabetes.
In our study, all studied individuals were of southern Han
Chinese ancestry and were residing in the metropolitan
area of Shanghai aged 50-82 years. Briefly, a total of 2598
eligible participants (1106 men and 1492 women) were
recruited. After excluding those who had previously diag-
nosed as type 2 diabetes and treated (n = 79), 2,519 indivi-
duals were eligible for the present analysis. Written
consent was obtained from all the participants. The study
was approved by the institutional review broad of Huashan
Hospital.
Data collection
A standardized questionnaire was used by trained physi-
cians to collect information such as age, sex, smoking
(yes/no), alcohol drinking (yes/no), and self-reported
diabetes, hypertension, dyslipidemia. According to parti-
cipants’ responses to the corresponding questions,
family history of diabetes was classified as yes or no.
All subjects were assessed after overnight fasting for at
least 10 h. The details of anthropometric measurements
including height, weight, waist circumference, hip cir-
cumference and blood pressure were carried by trained
physicians. BMI was calculated as weight in kilograms
divided by the square of height in meters and categor-
ized as normal weight (< 24.0 kg/m
2), or overweight
(24-28 kg/m
2), or obesity (≥ 28.0 kg/m
2), according to
the criteria for Chinese individuals [15].
Laboratory measurements
Peripheral venous blood samples were collected. The
fasting glucose, glucose 2 h after oral glucose tolerance
test, total cholesterol, triglycerides, LDL-cholesterol and
HDL-cholesterol were measured on an automatic analy-
zer (Hitachi 7080). Fasting insulin was determined by
radioimmunoassay (Linco Research, St. Charles, MO).
Insulin resistance was estimated using homeostasis
model assessment index-insulin resistance (HOMA-IR).
Type 2 diabetes and prediabetes were defined by 2005
ADA criteria [16]. A fasting glucose level lower than
5.6 mmol/l and a 2 h OGTT plasma glucose level below
7.8 mmol/l were defined as normal glucose regulation
(NGR). Impaired fasting glucose (IFG) and impaired glu-
cose tolerance (IGT) were defined as fasting glucose 5.6 to
6 . 9m m o l / la n d2hO G T Tp l a s m ag l u c o s e7 . 8t o
11.0 mmol/l respectively. Of 2519 participants, 392 had
type 2 diabetes (screen-detected and treatment-naive), 335
had isolated-IFG (all screen-detected and treatment-
naive), 353 had isolated-IGT (all screen-detected and
treatment-naive), 296 had IFG + IGT (all screen-detected
and treatment-naive) and 1143 had NGR.
Measurements of serum CRP, adiponectin, CXCL5 and
lipocalin-2
The serum CRP, adiponectin, CXCL5 and lipocalin-2
were determined in duplicate by ELISA with Duoset kit
(DY1707, DY1065, DY254 and DY1757, R&D Systems)
as recommended by the manufacturer. The ELISA sys-
tem had an intraassay coefficient of variation of 3.1-9.5%
and an interassay coefficient of variation of 4.3-10.7%,
respectively.
Statistical analysis
Normally distributed data were expressed as means ± SD,
whereas variables with a skewed distribution were
reported as median (interquartile range) and log trans-
formed to approximate normality before analysis. Cate-
gorical variables were represented by frequency and
percentage. Univariate and multivariable stepwise regres-
sion analysis were used to investigate the association of
serum lipocalin-2 with clinical and biochemical charac-
teristics. The stepwise regression procedure was used to
obtain determinants of serum lipocalin-2, potential con-
founding variables including age, gender, smoking, alco-
hol drinking, family history of diabetes, serum CRP,
serum adiponectin, serum CXCL5, HOMA-IR, BMI,
waist circumference, and waist/hip ratio were controlled
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impaired glucose regulation (IGR) with lipocalin-2, we
defined subjects with normal glucose regulation as 0 (n =
1143), and impaired glucose regulation as 1 (n = 984),
and excluded type 2 diabetic patients from logistic
regression analysis. For the association of combined
impaired glucose regulation and type 2 diabetes with
lipocalin-2, we defined subjects with normal glucose reg-
ulation as 0 (n = 1143) and combined impaired glucose
regulation and type 2 diabetes as 1 (n = 1376) in the
logistic regression analyses. Homogeneity of groups was
determined when the means showed significant differ-
ences. Means of these groups were compared by the Stu-
dent-Newman-Keuls method. All statistical analysis was
performed with the SPSS Statistical Package (version
13.0; SPSS Inc., Chicago, IL). A p value of less than 0.05
was considered to be statistically significant.
Results
General characteristics of the study participants
Our study involved 1143 subjects with NGR and 392
with newly diagnosed type 2 diabetes (Table 1). Among
those with impaired glucose regulation, 335 had isolated
IFG, 353 had isolated IGT, and 296 had IFG + IGT.
There was no significant difference in sex distribution,
alcohol drinking and serum LDL-c levels between these
groups. The NGR and diabetes groups had the most
favorable and unfavorable metabolic profiles, respec-
tively. There was no significant difference in waist cir-
cumference, waist/hip ratio, and serum triacylglycerol
levels between groups with isolated IFG, isolated IGT
and IFG + IGT.
Determinants of serum lipocalin-2 concentrations
Body mass index, waist circumference, log10 fasting serum
insulin, log10 HOMA-IR, total cholesterol, HDL-choles-
terol and serum CXCL5 levels were independent determi-
nants for serum lipocalin-2 concentrations in the stepwise
linear regression analysis (Table 2). In univariate analysis,
serum lipocalin-2 levels were closely associated with
serum C-reactive protein (r = 0.131, p < 0.001). However,
serum C-reactive protein was not an independent determi-
nant for serum lipocalin-2 (p > 0.05).
Lipocalin-2 distribution in different glucose metabolism
status
Serum lipocalin-2 levels were significantly associated with
fasting plasma glucose (r = 0.107, p < 0.001) and 2 h
OGTT plasma glucose (r = 0.066, p = 0.009) in total popu-
lation. Serum lipocalin-2 concentrations were significantly
higher in subjects with isolated IFG, isolated IGT, IFG +
IGT, and newly diagnosed type 2 diabetes compared with
those of subjects with NGR (83.5, 92.4, 83.1, 89.2 ng/ml vs
69.2 ng/ml, respectively, all p < 0.01) after adjustment for
age, gender, BMI, and family history of diabetes. There
was no statistical difference between the four groups with
glucose metabolism dysregulation (all p > 0.05, Figure 1).
Remarkably, as presented in Table 3, elevated lipocalin-2
was associated with increased risk of hyperglycemia. Ele-
vated serum lipocalin indicated high risk for impaired glu-
cose regulation (OR 1.30, 95% CI 1.23-1.62, p = 0.009)
after adjustment for age, gender, smoking, alcohol drink-
ing, family history of diabetes, serum CRP, serum adipo-
nectin, serum CXCL5, HOMA-IR, BMI, waist/hip ratio,
serum triacylglycerol, total cholesterol, HDL-cholesterol
and LDL-cholesterol. The OR for subjects with impaired
glucose regulation and type 2 diabetes was 1.31 (95% CI
1.21-1.69, p < 0.001).
Discussion
In this study, we found a strong correlation between
serum lipocalin-2 levels and impaired glucose regulation
as well as type 2 diabetes in a middle-aged and elderly
Chinese population. Moreover, this association is inde-
pendent of potential confounders.
Lipocalin-2 has been reported to be elevated in certain
metabolic disorders, including obesity, polycystic ovary
syndrome and type 2 diabetes [11,13,17]. In this study,
we also observed serum Lipocalin-2 elevation in both
type 2 diabetes and impaired glucose regulation. We
speculate that lipocalin-2 might be involved in the regu-
lation of glucose metabolism. This hypothesis is sup-
ported by several lines of evidence. First, lipocalin-2
knockout mice show significantly decreased fasting glu-
cose and insulin levels and improved insulin sensitivity
compared with their wild-type littermates [12]. Second,
Yan et al. demonstrated that lipocalin-2 could partially
block the suppressive effects of insulin on glucose pro-
duction and glucose 6-phosphatase expression in hepa-
tocytes. Finally, cells with reduction of lipocalin-2
showed elevated glucose uptake [10].
Pancreatic b-cell dysfunction and insulin resistance are
hallmarks of type 2 diabetes. We found that fasting
serum insulin and HOMA-IR were clearly associated
with lipocalin-2 even in stepwise regression analysis, sug-
gesting that this protein might be an indicator for b cell
function and insulin resistance in humans. Lipocalin-2
h a sb e e np r o p o s e dt ob ea ni r o nd e l i v e r yp r o t e i n[ 1 8 ] .
Lipocalin-2 delivers iron to the cytoplasm. Iron-loaded
lipocalin-2 increases intracellular iron. Iron excess might
result in b cell oxidative stress and impaired insulin
secretary capacity [19]. Iron deficiency has been related
to improved insulin sensitivity in animal models [20,21].
Epidemiologic studies also have confirmed the associa-
tion between iron overload and peripheral insulin resis-
tance [22]. Furthermore, lipocalin-2 delivers iron to the
cytoplasm where it activates ferritin, an iron-responsive
gene [18]. Recent study has demonstrated that elevated
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Page 3 of 8Table 1 Characteristics of the study population
Characteristics NGR (1) IGR P value Homogeneity of groups
Isolated IFG (2) Isolated IGT (3) IFG+IGT (4) Type 2 diabetes (5)
n 1143 335 353 296 392 - -
Male, n (%) 502 (43.9) 121 (36.1) 164 (46.5) 116 (39.2) 173 (44.1) 0.55 -
Age (years) 57.3 ± 75.69 58.2 ± 7.0 60.8 ± 8.4 60.2 ± 8.5 60.9 ± 8.3 < 0.001 (1,2) (3,4) (3,5)
Current smoking, n (%) 211 (18.5) 92 (27.5) 79 (22.4) 58 (19.6) 117 (29.8) 0.25 -
Alcohol drinking, n (%) 135 (11.8) 41 (12.2) 46 (13.0) 29 (9.8) 57 (14.5) 0.89 -
BMI (kg/m2) 24.2 ± 3.3 24.7 ± 3.4 25.1 ± 3.2 25.4 ± 3.5 25.8 ± 3.5 < 0.001 (1) (2) (3,4) (4,5)
Waist circumference (cm) 81.3 ± 8.5 83.3 ± 9.7 85.1 ± 8.5 85.9 ± 9.9 87.3 ± 9.0 < 0.001 (1) (2,3,4) (4,5)
Waist/hip ratio 0.85 ± 0.06 0.87 ± 0.07 0.88 ± 0.07 0.89 ± 0.10 0.89 ± 0.06 < 0.001 (1) (2,3,4) (4,5)
Fasting plasma glucose (mmol/l) 5.3 ± 0.5 6.2 ± 0.3 5.5 ± 0.4 6.0 ± 0.4 7.4 ± 2.4 < 0.001 (1) (2,4) (3) (5)
2 h OGTT plasma glucose (mmol/l) 5.9 ± 0.9 6.1 ± 0.9 9.1 ± 0.9 9.2 ± 1.0 14.6 ± 4.1 < 0.001 (1,2) (3,4) (5)
Fasting serum insulin (μU/ml) 6.86 (4.83-9.94) 6.58
(3.97-9.69)
6.65
(4.47-9.77)
6.54 (4.38-9.62) 7.68
(4.92-11.68)
< 0.001 (1) (2,3,4) (4,5)
HOMA-IR 1.56 (1.06-2.39) 1.41
(0.65-2.22)
1.54
(0.95-2.31)
1.39 (0.74-2.33) 1.93
(1.00-3.32)
< 0.001 (1) (2,3) (4,5)
Systolic blood pressure (mmHg) 126 ± 17 130 ± 17 132 ± 17 135 ± 18 137 ± 18 < 0.001 (1) (2,3,4) (4,5)
Diastolic blood pressure (mmHg) 79 ± 9 81 ± 10 82 ± 11 83 ± 10 83 ± 10 < 0.001 (1) (2,3, 4,5)
Triglycerides (mmol/l) 1.26 (0.90-1.81) 1.40 (0.92-1.95) 1.45
(0.96-2.13)
1.35 (0.95-2.12) 1.57
(1.10-2.28)
< 0.001 (1) (2,3,4) (5)
Total cholerterol (mmol/l) 5.38 ± 1.04 5.32 ± 0.93 5.54 ± 1.07 5.34 ± 1.07 5.59 ± 1.06 0.03 (1,2,3, 4) (5)
LDL cholesterol (mmol/l) 3.13 ± 0.78 3.11 ± 0.69 3.22 ± 0.90 3.18 ± 0.91 3.29 ± 0.87 0.21 (1,2,3, 4) (5)
HDL cholesterol (mmol/l) 1.45 ± 0.51 1.41 ± 0.32 1.35 ± 0.33 1.28 ± 0.31 1.30 ± 0.62 < 0.001 (1,2) (3,4,5)
CRP (μg/ml) 2.41 (1.11-4.95) 2.35 (1.18-4.99) 3.58 (1.61-6.56) 2.73 (1.37-5.48) 3.53 (1.62-7.22) < 0.001 (1) (2) (3,4,5)
CXCL5 (pg/ml) 1.7 ± 1.3 1.8 ± 1.3 1.9 ± 1.4 1.8 ± 1.2 1.9 ± 1.9 0.03 (1) (2,3, 4,5)
Adiponectin (μg/ml) 10.42 (7.19-14.62) 9.93 (6.58-13.88) 9.47 (6.71-13.62) 10.11 (7.08-13.84) 9.04 (6.12-12.55) < 0.001 (1) (2,3, 4,5)
Lipocalin-2 (ng/ml) 69.2 ± 7.8 83.5 ± 8.9 92.4 ± 10.7 83.1 ± 8.6 89.2 ± 8.3 < 0.001 (1) (2,3, 4,5)
Data are means ± SD, n (%), or median (interquartile range)
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8circulating ferritin concentrations are associated with
high risk for type 2 diabetes and metabolic syndrome
[23]. Thus, we postulate that Lipocalin-2 might influence
b cell function and insulin sensitivity partially through
mediation of iron.
Increasing evidences suggest a critical role for PPARg
in the regulation of insulin sensitivity. However, the
exact role of lipocalin-2 in obesity-induced insulin resis-
tance remains controversial. Jin et al. observed devel-
oped insulin resistance and decreased adipose
PPARgexpression in the absence of lipoclain-2 mice,
suggesting that lipocalin-2 is a critical selective modula-
tor of PPARgactivation [24]. Jun et al. observed no dif-
ference in insulin sensitivity in lipocalin-2 knock out
Table 2 Univariate and stepwise regression analysis with serum lipocalin-2 concentration as a dependent variable
Co-variable Univariate Stepwise
r b(SEM) p value b(SEM) p value
Age (years) 0.000 -0.002 (0.001) 0.497 - -
Sex (male = 1, female = 2) 0.086 0.033 (0.020) 0.001 - -
Body mass index (kg/m2) 0.058 0.015 (0.004) 0.018 0.160 (0.004) < 0.001
Waist circumference (cm) 0.118 0.000 (0.007) < 0.001 0.105 (0.001) 0.012
Waist/hip ratio 0.081 0.151 (0.580) 0.005 - -
Fasting plasma glucose (mmol/l) 0.107 0.011 (0.009) < 0.001 - -
2h OGTT plasma glucose (mmol/l) 0.066 0.005 (0.003) 0.009 - -
Log10 fasting serum insulin (μU/ml) 0.263 0.140 (0.050) < 0.001 0.105 (0.045) 0.007
Log10 HOMA-IR 0.291 0.123 (0.031) < 0.001 0.209 (0.025) < 0.001
Log10 triacylglycerol (mmol/l) 0.134 0.054 (0.053) < 0.001 - -
Total cholesterol (mmol/l) -0.087 0.031 (0.019) < 0.001 -0.075 (0.008) 0.006
HDL- cholesterol (mmol/l) -0.181 -0.041 (0.037) < 0.001 -0.092 (0.026) 0.002
LDL- cholesterol (mmol/l) -0.059 0.009 (0.020) 0.016 - -
Systolic blood pressure (mmHg) 0.081 0.001 (0.001) 0.002 - -
Diastolic blood pressure (mmHg) 0.101 0.000 (0.001) < 0.001 - -
CRP (μg/ml) 0.131 0.021 (0.021) < 0.001 - -
CXCL5 (pg/ml) 0.076 0.084 (0.026) 0.003 0.08 (0.025) 0.002
Adiponectin (μg/ml) -0.095 0.015 (0.035) < 0.001 - -
b, Regression coefficient; r, Pearson correlation coefficient; SEM standard error of mean
Figure 1 Adjusted means (± SEM) of serum lipocalin-2 concentrations in subjects with NGR(normal glucose regulation), IGR (isolated
IFG[i-IFG], isolated IGT[i-IFGT] and IFG + IGT) and type 2 diabetes (T2DM). The covariables included age, gender, BMI and family history of
diabetes. Subjects with type 2 diabetes and IGR (i-IFG, i-IGT and IFG + IGT) had higher concentrations of lipocalin-2 than those with NGR (both p
< 0.01). There was no statiscal difference among the subgroups of IGR (p = 0.29) and between the IGR and type 2 diabetes (p = 0.37).
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Page 5 of 8mice on high-fat-diet [25]. However, our study demon-
strated that serum concentrations of lipocalin-2 in
humans were associated with insulin sensitivity as mea-
sured by the HOMA-IR. Consistent with our study,
other study have also demonstrated that treatment with
the peroxisome proliferator-activated receptor agonist
rosiglitazone markedly decreased lipocalin-2 expression
in mice and circulating concentrations in both mice and
human [11]. Thus, further prospective large population-
based studies are needed to investigate the role of lipo-
calin-2 in obesity–induced insulin resistance.
Visceral fat accumulation has been well-associated with
adipose tissue inflammation and insulin resistance [26].
In present study, we found that waist circumference,
rather than waist/hip, is one of the independent determi-
nants of serum lipocalin-2 levels. It has been well-docu-
mented that waist circumference reflects the amount of
visceral adipose tissue, which is closely correlated with
the development of metabolic disorders. Hence, the accu-
mulated visceral fat might account for the serum lipoca-
lin-2 elevation during insulin resistance. In line with our
hypothesis, some studies have demonstrated that lipoca-
lin-2 is selectively expressed in mouse epididymal fat
depot and its expression is highly induced during adipo-
cyte differentiation [27,28]. Moreover, the expression of
lipocalin-2 in visceral adipose tissue was found to be cor-
related with its circulating levels in animal models [13].
Certainly, more work is urgently needed to clarify
whether visceral adipose tissue plays a causal role in the
elevation of lipocalin-2.
Type 2 diabetes was associated with wide pathophysiolo-
gical pathways, including inflammation [29]. CRP is a pat-
tern-recognition molecule of innate immunity as an acute-
phase reactant and a hallmark of low-grade systemic
inflammation. We confirmed the strong and positive asso-
ciation between lipocalin-2 and CRP levels observed in
previous studies [11], suggesting elevated serum lipocalin-
2 in prediabetes and type 2 diabetes might associate with
chronic inflammation. Previous studies have demonstrated
that circulating CRP is an independent risk factor for type
2 diabetes and atherosclerosis [30,31]. Yan et al. found
that IL-1b and TNFa are both strong inducers of lipoca-
lin-2 production [10]. Another study shows that lipocalin-
2 directly stimulates the expression and activity of
12-lipoxygenase as well as TNF-a production in fat tissue.
Conversely, these changes were attenuated in lipocalin-2
deficient mice [12]. These findings suggested that lipoca-
lin-2 might play a causal role in the pathogenesis of
inflammation. However, lipocalin-2 has recently been
claimed to exert antiinflammatory function, and these
effects were associated with its modulation of PPARg
activity via direct or indirect mechanisms by inhibiting
NFkB activity [27]. In our study we found that CRP is not
an independent risk of lipocalin-2. With the cross-sec-
tional nature, we are limited in the ability to evaluate
whether elevated lipocalin-2 is a protective mechanism
against overactivaion of inflammation or an inflammation
inducer.
One of the interesting findings of the present study is
that the concentration of lipocalin-2 is also associated
with CXC ligand 5 (CXCL5). Elevated CXCL5 levels
were strongly and independently associated with insulin
resistance [32]. CXCL5 is an adipose tissue derived fac-
tor that links obesity with insulin resistance. CXCL5
blocks insulin signaling by activating the Jak2/STAT5/
SOCS2 pathway. CXCL5 levels were also demonstrated
to have a positive association with inflammatory factor
CRP in our previous study [14]. Taken together, lipoca-
lin-2 and CXCL5, as innate immunity indicators, are
both serum markers of low-grade systemic inflammatory
response and could potentially modulate chronic inflam-
matory processes.
To our knowledge, this is the first study to investigate
the association of serum lipocalin-2 and the develop-
ment of type 2 diabetes as well as impaired glucose reg-
u l a t i o ni nC h i n e s e .T h em a i ns t r e n g t ho fo u rs t u d yi s
that all diabetic participants were newly diagnosed.
None had used glucose-lowering treatment or insulin.
Hence, the confounding effect of glucose-lowering treat-
ment could be excluded. Anyway, there are still some
Table 3 The risk of impaired glucose regulation and type 2 diabetes associated with a 10 ng/ml increase in serum
lipocalin-2
Model IGR (n = 984) p value
a impaired glucose regulation and type 2 diabetes (n = 1376) p value
b
Model 1 1.48 (1.34-1.87) < 0.001 1.55 (1.43-1.97) < 0.001
Model 2 1.43 (1.31-1.75) < 0.001 1.47 (1.38-1.85) < 0.001
Model 3 1.40 (1.31-1.81) < 0.001 1.41 (1.29-1.81) < 0.001
Model 4 1.35 1.24-1.65) < 0.001 1.38 (1.25-1.81) < 0.001
Model 5 1.30 (1.23-1.62) 0.009 1.31 (1.21-1.69) < 0.001
Values are ORs (95% CI)
Model 1: Unadjusted. Model 2: Adjusted for age, sex, smoking (yes/no), alcohol drinking (yes/no), family history of diabetes (yes/no). Model 3: Further adjusted
for HOMA-IR, BMI, waist/hip ratio and adiponectin. Model 4: Further adjusted for serum triacylglycerol, total cholesterol, HDL- and LDL-cholesterol. Model 5:
Further adjusted for inflammatory factors (CRP and CXCL5).
aFor the risk of IGR, we defined subjects with normal glucose regulation as 0 (n = 1143) and IGR as 1
(n = 984), excluding type 2 diabetes (n = 392) from the analysis.
bFor the risk of combined IGR and type 2 diabetes, we defined subjects with normal glucose
regulation as 0 (n = 1143) and combined IGR and type 2 diabetes as 1 (n = 1376).
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measured in this study, some patients with diabetes
might have been missed. Second, No causal relationship
between lipocalin-2 levels and the risk of impaired glu-
cose regulation or diabetes can be drawn, since the
study was cross-sectional designed.
Conclusion
In conclusion, our study indicates that serum lipocalin-2
is independently correlated with impaired glucose regu-
lation and type 2 diabetes. Although the underlying
pathophysiological mechanisms remain unclear, it seems
that insulin resistance and chronic low-grade systematic
inflammation may be involved in this association.
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